Overview

Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

Status:
Terminated

Trial end date:
2014-11-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate oral doses of BMS-754807 in combination with letrozole or BMS-754807 alone are safe and efficacious in locally advanced or metastatic hormone receptor positive breast cancer subjects who have progressed with prior non-steroidal aromatase inhibitor treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

Mayo Clinic

Treatments:

Aromatase Inhibitors
Hormones
Letrozole